Abstract
Diffuse large B-cell lymphoma (DLBCL) is the commonest form of lymphoid malignancy, with a prevalence of about 40% worldwide. Its classification encompasses a common form, also termed as “not otherwise specified” (NOS), and a series of variants, which are rare and at least in part related to viral agents. Over the last two decades, DLBCL-NOS, which accounts for more than 80% of the neoplasms included in the DLBCL chapter, has been the object of an increasing number of molecular studies which have led to the identification of prognostic/predictive factors that are increasingly entering daily practice. In this review, the main achievements obtained by gene expression profiling (with respect to both neoplastic cells and the microenvironment) and next-generation sequencing will be discussed and compared. Only the amalgamation of molecular attributes will lead to the achievement of the long-term goal of using tailored therapies and possibly chemotherapy-free protocols capable of curing most (if not all) patients with minimal or no toxic effects.
Funder
Associazione Italiana per la Ricerca sul Cancro
Reference61 articles.
1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues;Swerdlow,2017
2. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]
3. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues;Jaffe,2001
4. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues;Swerdlow,2008
5. Comparison of a Standard Regimen (CHOP) with Three Intensive Chemotherapy Regimens for Advanced Non-Hodgkin's Lymphoma
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献